Status:
COMPLETED
Myeloproliferative Neoplasms (MPN) and COVID-19
Lead Sponsor:
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Collaborating Sponsors:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions:
Myeloproliferative Neoplasm
COVID
Eligibility:
All Genders
18+ years
Brief Summary
An increased risk of both venous and arterial thromboembolism was noted in reports from SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from patients who experienced s...
Detailed Description
This is an European multicenter observational study that will include around 550 MPN patients with a confirmed diagnosis of Covid-19 will be followed for at least one month. Detailed information on th...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Confirmed diagnosed of MPN according to WHO criteria
- Diagnosis of COVID-19 based by the positivity of oropharyngeal swab performed between 15 February 2020 up to 15 February 2022
- Signed informed consent
Exclusion
- None
Key Trial Info
Start Date :
May 13 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2022
Estimated Enrollment :
552 Patients enrolled
Trial Details
Trial ID
NCT04385160
Start Date
May 13 2020
End Date
August 31 2022
Last Update
September 15 2025
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
New York-Presbyterian/Weill Cornell Medical Center
New York, New York, United States, 10065
2
National Specialised Hospital for Active Treatment of Hematological Diseases
Sofia, Bulgaria
3
University hospital Dubrava-School of Medicine University of Zagreb
Zagreb, Croatia
4
Hopital Saint-Louis
Paris, France